Bridge­Bio's $250M of­fer­ing; Vi­iV's PhI da­ta for ul­tra-long-act­ing HIV treat­ment

Plus, news about Viking Ther­a­peu­tics, Ar­cutis Bio­ther­a­peu­tics, Akari and Peak Bio:

Bridge­Bio’s stock sale: The com­pa­ny an­nounced plans to raise $250 mil­lion the same day that Bay­er said it is pur­chas­ing the Eu­ro­pean rights to aco­ramidis, Bridge­Bio’s AT­TR amy­loi­do­sis with car­diomy­opa­thy treat­ment can­di­date. Bridge­Bio’s shares $BBIO were down 7% Tues­day morn­ing. — Lei Lei Wu

Vi­iV Health­care touts PhI HIV treat­ment da­ta: The com­pa­ny’s ul­tra-long-act­ing for­mu­la­tion of the an­ti­retro­vi­ral cabote­gravir can be in­ject­ed at in­ter­vals of at least four months, per da­ta from the Phase I test. Cabote­gravir is one of the ac­tive in­gre­di­ents in Cabe­nu­va. HIV treat­ment shots are cur­rent­ly giv­en once a month or every oth­er month. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER